Stockscreener 앱 받기
3.159
0.96%
0.029
전일 마감가:
$3.13
열려 있는:
$3.17
하루 거래량:
89,942
Relative Volume:
0.07
시가총액:
$526.01M
수익:
-
순이익/손실:
$-54.70M
주가수익비율:
-11.28
EPS:
-0.28
순현금흐름:
$-51.36M
1주 성능:
-0.94%
1개월 성능:
-11.48%
6개월 성능:
-26.51%
1년 성능:
-15.28%
1일 변동 폭
$3.15
$3.24
1주일 범위
$2.815
$3.24
52주 변동 폭
$2.815
$5.70
사바라 Stock (SVRA) Company Profile
명칭
Savara Inc
전화
51285113796
주소
6836 BEE CAVE ROAD, AUSTIN, TX
SVRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| SVRA | 3.17 | 526.01M | 0 | -54.70M | -51.36M | -0.28 |
| VRTX | 447.65 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.99 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.27 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.68 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.49 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
사바라 Stock (SVRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-07 | 개시 | Guggenheim | Buy |
| 2023-05-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-31 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-03-16 | 개시 | Piper Sandler | Overweight |
| 2021-03-15 | 개시 | Oppenheimer | Outperform |
| 2019-06-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-13 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | 재개 | ROTH Capital | Neutral |
| 2018-01-03 | 개시 | Ladenburg Thalmann | Buy |
| 2017-09-27 | 재개 | ROTH Capital | Buy |
| 2017-09-22 | 개시 | Jefferies | Buy |
| 2017-09-11 | 개시 | JMP Securities | Mkt Outperform |
모두보기
사바라 주식(SVRA)의 최신 뉴스
Independent Director of Savara Picks Up 4.5% More Stock - Simply Wall St
Savara Inc. Reports Third-Quarter Financial Results and Announces Key Regulatory Milestones - MSN
Insider Buying Alert: Joseph Mccracken Acquires 20,000 Shares of Savara Inc (SVRA) - GuruFocus.com
Savara director Joseph McCracken acquires $59,071 in common stock - Investing.com India
Director David Ramsay Acquires 100,000 Shares of Savara Inc (SVR - GuruFocus.com
Savara Inc director David Ramsay buys $287,600 in common stock - Investing.com
Savara Inc director David Ramsay buys $287,600 in common stock By Investing.com - Investing.com UK
Savara (NASDAQ:SVRA) Shares Down 8.5%Time to Sell? - MarketBeat
Prudential Financial Inc's Strategic Acquisition of Savara Inc S - GuruFocus.com
What is HC Wainwright's Estimate for Savara FY2024 Earnings? - MarketBeat
Evercore ISI Reiterates In-Line Rating for Savara (NASDAQ:SVRA) - Defense World
Savara (NASDAQ:SVRA) Reaches New 1-Year Low on Analyst Downgrade - MarketBeat
SVRA stock touches 52-week low at $3.27 amid market challenges - Investing.com India
500: Something went wrong - Investing.com Canada
Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate - GuruFocus.com
Savara downgraded at Evercore on manufacturing concerns for lung disease candidate - Seeking Alpha
Savara (NASDAQ:SVRA) Shares Gap Down on Analyst Downgrade - MarketBeat
Savara (NASDAQ:SVRA) Price Target Lowered to $6.00 at HC Wainwright - MarketBeat
Savara (NASDAQ:SVRA) Earns "In-Line" Rating from Evercore ISI - MarketBeat
Savara (SVRA) to Present at Jefferies and Piper Sandler Healthcare Conferences | SVRA Stock News - StockTitan
Jennison Associates LLC's Strategic Acquisition of Savara Inc Sh - GuruFocus.com
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
Savara Inc (NASDAQ:SVRA) Receives $11.17 Average Price Target from Analysts - MarketBeat
Savara Inc. to Participate in Guggenheim Inaugural Healthcare Conference - MyChesCo
Savara Fast-Tracks MOLBREEVI FDA Filing Despite Widening Q3 Losses, $219M Cash Runway | SVRA Stock News - StockTitan
Wellington Management Group LLP's Strategic Acquisition in Savar - GuruFocus.com
SVRASavara Inc. Latest Stock News & Market Updates - StockTitan
Savara (NASDAQ:SVRA) Stock Price Down 5.1%Should You Sell? - MarketBeat
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference - StockTitan
Savara Inc. Shines Spotlight on Rare Lung Disease in New TV Feature - MSN
Savara Inc. Rewards New Employees with Inducement Awards - MSN
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV - Business Wire
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of "The Balancing Act®" Airing on Lifetime® TV - Yahoo Canada Finance
Savara Announces New Employment Inducement Grant - Business Wire
Savara Inc (NASDAQ:SVRA) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Savara Announces New Employment Inducement Grant | SVRA Stock News - StockTitan
Savara Inc (SVRA) deserves deeper analysis - US Post News
Ratio Review: Analyzing Savara Inc (SVRA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Savara Inc (SVRA) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
Savara Inc. Launches Early Access Program for Rare Lung Disease Treatment - MSN
Savara maintains Overweight rating from Piper Sandler on bullish aPAP therapy prospects - Investing.com UK
Savara (NASDAQ:SVRA) Trading Down 3.4%Here's What Happened - MarketBeat
Cantaloupe, Inc. Executives Boost Confidence with Significant Stock Purchases - MyChesCo
Savara stock outlook steady as H.C. Wainwright highlights challenges in doctor engagement at CHEST meeting - Investing.com
Savara (NASDAQ:SVRA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Should investors be concerned about Savara Inc (SVRA)? - US Post News
The growth track for Savara Inc (SVRA) has changed recently - SETE News
Stock Surge: Savara Inc (SVRA) Closes at 3.82, Marking a 0.26 Increase/Decrease - The Dwinnex
Marshall Wace LLP Has $1.23 Million Stake in Savara Inc (NASDAQ:SVRA) - MarketBeat
Algert Global LLC Boosts Stock Position in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc. Grants Inducement Awards to New Employee - MSN
사바라 (SVRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
사바라 주식 (SVRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RAMSAY DAVID A | Director |
Nov 18 '24 |
Buy |
2.88 |
100,000 |
287,600 |
2,323,642 |
| Pauls Matthew | CHIEF EXECUTIVE OFFICER |
Dec 28 '23 |
Sale |
4.71 |
84,000 |
395,900 |
1,302,674 |
| Lowrance David L | CHIEF FINANCIAL OFFICER |
Dec 28 '23 |
Sale |
4.71 |
10,000 |
47,131 |
342,355 |
| Elam Nevan C | Director |
Dec 28 '23 |
Option Exercise |
1.30 |
53,758 |
69,722 |
116,343 |
| Elam Nevan C | Director |
Dec 28 '23 |
Sale |
4.71 |
93,843 |
442,291 |
22,500 |
| Hawkins Richard J | Director |
Dec 11 '23 |
Option Exercise |
0.82 |
10,841 |
8,890 |
12,741 |
| Elam Nevan C | Director |
Dec 11 '23 |
Option Exercise |
0.82 |
10,841 |
8,890 |
40,085 |
0.42%
0.16%
자본화:
|
볼륨(24시간):